SCHEMBL156135

SCHEMBL156135

CC(=O)OOc1ccc(Cl)cc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HPGD P15428 1/20 0.47
KMT2A Q03164 5/20 0.46
MEN1 O00255 4/20 0.46
PPARA Q07869 3/20 0.46
CYP1A2 P05177 2/20 0.46
CYP3A4 P08684 2/20 0.46
CYP2D6 P10635 1/20 0.46
MAPT P10636 1/20 0.46
CYP2C19 P33261 1/20 0.46
MAOA P21397 2/20 0.43
MAOB P27338 2/20 0.43
ALOX15 P16050 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.41
ELANE P08246 1/20 0.41
FABP2 P12104 1/20 0.40
PPARG P37231 1/20 0.40
SLC22A12 Q96S37 1/20 0.40
ABCB11 O95342 1/20 0.40
TSHR P16473 1/20 0.40
HTR2A P28223 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Ammonia Solution, Strong SCHEMBL22437492 0.98 HPGD (0.46) HPGDKMT2AMEN1PPARACYP1A2
SCHEMBL31532258 0.98 MEN1 (0.46) HPGDKMT2AMEN1PPARACYP1A2
SCHEMBL27406073 0.98 HPGD (0.46) HPGDKMT2AMEN1PPARACYP1A2
Diethanolamine SCHEMBL25288907 0.85 KDM4E (0.46) KMT2ACYP1A2CYP2D6CYP2C19MAOA
SCHEMBL10727330 0.82 CYP1A2 (0.44) KMT2AMEN1PPARACYP1A2MAPT
SCHEMBL25288908 0.82 MAOA (0.36) HPGDKMT2AMEN1PPARACYP1A2
SCHEMBL10438873 0.80 LMNA (0.61) HPGDCYP3A4MAPTMAOBSMN1; SMN2
SCHEMBL6200881 0.80 MEN1 (0.44) KMT2AMEN1CYP3A4MAPTELANE
SCHEMBL8586307 0.80 CES2 (0.52) KMT2AMEN1MAPTSMN1; SMN2CES2
SCHEMBL28617865 0.79 RAB9A (0.46) HPGDKMT2AMEN1CYP2D6MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 247 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1558220-B1 ORAL COMPOSITIONS FOR TREATMENT OF DIABETES WOCKHARDT LTD (IN) 2010-02-10 EP claimed
CN-1684682-A Small organic molecules that increase the activity of gelatinase A in ocular cells BAUSCH & LOMB (US) 2005-10-19 CN claimed
CN-1503626-A Herbicidal composition containing benzoylcyclohexanediones and safeners �Ϻ���ͨ��ѧ 2004-06-09 CN claimed
US-20260076972-A1 ANTIDIABETIC MEDICATIONS BOEHRINGER INGELHEIM INT (DE) 2026-03-19 US disclosed
EP-4701626-A1 AMORPHOUS OBICETRAPIB AND SGLT2 INHIBITOR COMBINATION NewAmsterdam Pharma B.V. (NL) 2026-03-04 EP disclosed
EP-4642434-A2 LIPID COMPOSITIONS ON THE BASIS OF IONIZABLE LIPIDS, USE FOR DELIVERY TO IMMUNE CELLS Life Technologies Corporation (US) 2025-11-05 EP disclosed
US-12458700-B2 Amine-containing transfection reagents and methods for making and using same Life Technologies Corporation (US) 2025-11-04 US disclosed
WO-2025151874-A1 INDOLE ALKALOID ANTIPLASMODIAL AGENTS AND PREPARATION THEREOF UNIVERSITY OF CENTRAL FLORIDA RESEARCH FOUNDATION, INC. (US) 2025-07-17 WO disclosed
US-20250170128-A1 Obicetrapib and SGLT2 Inhibitor Combination NEWAMSTERDAM PHARMA B.V. (NL) 2025-05-29 US disclosed
WO-2025072886-A9 OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF WAVE LIFE SCIENCES LTD. (SG) 2025-05-15 WO disclosed
EP-3654955-B1 PHARMACEUTICAL COMPOSITIONS LILLY CO ELI (US) 2025-05-07 EP disclosed
EP-0807118-A2 NOVEL COMPOUNDS AND METHODS FOR MAKING AND USING SAME GILEAD SCIENCES, INC. (US) 1997-11-19 EP disclosed
WO-1996023801-A2 NOVEL COMPOUNDS AND METHODS FOR MAKING AND USING SAME GILEAD SCIENCES, INC. (US) 1996-08-08 WO disclosed
EP-0661907-A2 Liquid-type transformerless thermal evaporating device EARTH CHEMICAL CO., LTD. (JP) 1995-07-05 EP disclosed
EP-0555938-A1 Use of phenoxyacetate derivatives for the restoration of neural function Albert ROLLAND S.A. (FR) 1993-08-18 EP disclosed
EP-0487623-A1 DERIVATIVES OF 5-AMINO-1,2,3,4 TETRAHYDRO-ACRIDINE AND APPLICATIONS AS DRUGS SYNTHESES ET RECHERCHES (FR) 1992-06-03 EP disclosed
WO-1991002725-A1 DERIVATIVES OF 5-AMINO-1,2,3,4 TETRAHYDRO-ACRIDINE AND APPLICATIONS AS DRUGS SYNTHESES ET RECHERCHES (FR) 1991-06-07 WO disclosed
EP-0117675-B1 BENZOFURAN AND BENZOTHIOPHENE-CARBOXYLIC-ACID DERIVATIVES BEECHAM GROUP PLC (GB) 1986-07-23 EP disclosed
US-4548948-A Anti-inflammatory and analgesic benzothiophene and benzafuran derivatives, compositions, and method of use therefor BEECHAM GROUP P.L.C. (GB) 1985-10-22 US disclosed
EP-0117675-A1 Benzofuran and benzothiophene-carboxylic-acid derivatives BEECHAM GROUP PLC (GB) 1984-09-05 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12458700-B2 Amine-containing transfection reagents and methods for making and using same SNRPA, NUDT21, SOAT2 HPGD 2842/4885KMT2A 908/4885MEN1 746/4885
US-20250170128-A1 Obicetrapib and SGLT2 Inhibitor Combination SLC5A2, SLC5A1, SLC2A2 HPGD 3914/4885KMT2A 220/4885MEN1 4550/4885
US-20260076972-A1 ANTIDIABETIC MEDICATIONS IAPP, DPP4, PYGL HPGD 4343/4885KMT2A 3992/4885MEN1 2843/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.